Key Points
- Regeneron director Kathryn Guarini sold 400 shares for $360,000 at an average price of $900, leaving her with 603 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The company reported quarterly revenue of $5.12 billion, up 36.3% year over year, and earnings of $20.07 per share, beating analyst estimates on both measures.
- Analyst views were mixed: several firms raised price targets after the results, while some maintained neutral ratings and targets below the recent share price, citing valuation concerns.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Kathryn Guarini sold 400 shares of the company's stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at approximately $542,700. This represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathryn Guarini also recently made the following trade(s):
- On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00.
- On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00.
Regeneron Pharmaceuticals Trading Up 1.3%
Regeneron Pharmaceuticals stock opened at $973.36 on Wednesday. The company's fifty day simple moving average is $798.74 and its 200-day simple moving average is $740.16. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $975.49. The stock has a market cap of $100.22 billion, a P/E ratio of 21.49, a P/E/G ratio of 1.51 and a beta of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the prior year, the business posted $11.83 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 36.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals's payout ratio is 8.30%.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% year over year and ahead of estimates, while earnings of $20.07 per share also topped consensus. Analysts pointed to strength in commercial products and progress in the pipeline as signs of underlying business health. REGN Q3 deep dive: pipeline progress and core brands drive outperformance
- Positive Sentiment: Following the results, multiple firms raised their price targets; some maintained Buy or Overweight ratings, and forecasts cited in coverage reached as high as $1,175. These revisions reflect improved expectations after the earnings beat. Analysts raise forecasts after upbeat Q3 results
- Neutral Sentiment: Director Kathryn Guarini sold 400 shares under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the sale may reduce its significance as a signal about the company’s outlook. SEC filing
- Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, with a 0.4% indicated yield. Management also scheduled appearances at upcoming healthcare investor conferences; neither announcement provides a major near-term earnings catalyst. Investor conference presentations
- Negative Sentiment: Despite raising targets, several firms—including RBC, Morgan Stanley, Bernstein and Wells Fargo—kept neutral-style ratings and set targets below the recent share price, signaling valuation caution after the stock’s rally. RBC comments on Regeneron’s Q3 results
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. University of Texas Texas AM Investment Management Co. increased its position in Regeneron Pharmaceuticals by 66.1% during the third quarter. University of Texas Texas AM Investment Management Co. now owns 98 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 39 shares during the period. Almanack Investment Partners LLC. raised its stake in Regeneron Pharmaceuticals by 9.6% during the 3rd quarter. Almanack Investment Partners LLC. now owns 711 shares of the biopharmaceutical company's stock valued at $539,000 after purchasing an additional 62 shares during the last quarter. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 24.9% during the 3rd quarter. Brighton Jones LLC now owns 5,400 shares of the biopharmaceutical company's stock valued at $4,094,000 after purchasing an additional 1,075 shares during the last quarter. Ethic Inc. boosted its holdings in Regeneron Pharmaceuticals by 3.1% in the 3rd quarter. Ethic Inc. now owns 16,570 shares of the biopharmaceutical company's stock valued at $12,564,000 after purchasing an additional 501 shares during the period. Finally, Parallel Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 8.9% in the 3rd quarter. Parallel Advisors LLC now owns 1,158 shares of the biopharmaceutical company's stock valued at $878,000 after purchasing an additional 95 shares during the period. 83.31% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
REGN has been the subject of a number of recent research reports. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an "equal weight" rating in a research note on Monday. UBS Group raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an "overweight" rating in a research note on Monday. Argus upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 price objective on the stock in a report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Regeneron Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $898.97.
Get Our Latest Stock Report on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
